Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY4065967

Other · developed by ELI LILLY &

Phase 2 Most advanced trial
LLY Developer

What is LY4065967?

LY4065967 is an investigational agent studied in knee osteoarthritis, diabetic neuropathic pain, chronic low-back pain and diabetic peripheral neuropathic pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Musculoskeletal
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

Conditions studied

Chronic Low-back PainDiabetic Neuropathic PainDiabetic Peripheral Neuropathic PainOsteoarthritis, Knee

More from ELI LILLY &

Follow LLY, the company behind LY4065967

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.